Armata Pharmaceuticals

Historical price data

Armata Pharmaceuticals is a clinical-stage biotech focused on developing pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant infections, a critical global health threat. The company's core strategy is built on a vertically integrated platform that spans from natural phage discovery and synthetic engineering to in-house cGMP manufacturing and clinical development. Its lead programs target high-mortality infections like Pseudomonas aeruginosa in cystic fibrosis and Staphylococcus aureus bacteremia, aiming to provide a precise alternative to broad-spectrum antibiotics. Armata's fully controlled 56,000 sq. ft. facility in Los Angeles provides a strategic advantage in developing these complex biologic products.

A hybrid bacteriophage platform combining natural phage discovery with synthetic biology engineering to optimize phages for enhanced potency, spectrum, and pharmaceutical properties as targeted antimicrobial therapeutics.

Armata competes with a small group of clinical-stage phage therapy companies (e.g., Adaptive Phage Therapeutics, BiomX) and broader novel antimicrobial developers. Its key differentiators are in-house cGMP manufacturing and a hybrid natural/synthetic phage engineering platform.